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ABSTRACT
Background The lung volume reduction (LVR) coil is a
minimally invasive bronchoscopic nitinol device designed
to reduce hyperinflation and improve elastic recoil in
severe emphysema. We investigated the feasibility, safety
and efficacy of LVR coil treatment in a prospective
multicentre cohort trial in patients with severe
emphysema.
Methods Patients were treated in 11 centres. Safety
was evaluated by recording all adverse events, efficacy
by the St George’s Respiratory Questionnaire (SGRQ) as
primary endpoint, and pulmonary function testing,
modified Medical Research Council dyspnoea score
(mMRC) and 6-min walk distance (6MWD) up to
12 months after the final treatment.
Results Sixty patients (60.9 ± 7.5 years, forced
expiratory volume in 1 s (FEV1) 30.2 ± 6.3% pred) were
bronchoscopically treated with coils (55 bilateral,
5 unilateral), with a median of 10 (range 5–15) coils per
lobe. Within 30 days post-treatment, seven chronic
obstructive pulmonary disease exacerbations (6.1%),
six pneumonias (5.2%), four pneumothoraces (3.5%)
and one haemoptysis (0.9%) occurred as serious adverse
events. At 6 and 12 months, respectively, ΔSGRQ
was −12.1±12.9 and −11.1±13.3 points, Δ6MWD was
+29.7±74.1 m and +51.4±76 m, ΔFEV1 was +0.11
±0.20 L and +0.11±0.30 L, and ΔRV (residual volume)
was −0.65±0.90 L and −0.71±0.81 L (all p<0.01).
Post hoc analyses showed significant responses for
SGRQ, 6MWD and RV in patients with both
heterogeneous and homogeneous emphysema.
Conclusions LVR coil treatment results in significant
clinical improvements in patients with severe
emphysema, with a good safety profile and sustained
results for up to 1 year.
Trial registration number: NCT01328899.
INTRODUCTION
For patients with advanced chronic obstructive pul-
monary disease (COPD) who, despite optimal
medical management still have severe dyspnoea,
bronchoscopic lung volume reduction could be a
beneficial treatment option.1 2 Although lung
volume reduction surgery and lung transplantation
are still valid treatment modalities for patients with
COPD, the use of these interventions is very
limited because of strict patient selection criteria,
significant morbidity and donor shortage.3–5
To date, bronchoscopic lung volume reduction
using one-way endobronchial valves (EBV) has
been the most extensively investigated technique in
this field.6–8 However, successful clinical outcomes
from EBV therapy can only be achieved in patients
with no interlobar collateral ventilation and when
the one-way valves are placed to entirely block all
the airways into the target lobe, which can be tech-
nically difficult due to local anatomy and in the
absence of significant experience with these
devices.6–8 It is estimated that only about 33% of
patients with severe emphysema have no collateral
ventilation between the target and adjacent lobe
and can thus potentially be treated using one-way
valves.1 This clearly shows the need for alternative
bronchoscopic treatments that work independently
of the presence of collateral ventilation.
In 2010 we reported the first human trial using
bronchoscopically delivered nitinol lung volume
reduction (LVR) coils.9 Up to six shape-memory
coils per lung were placed in patients with severe
emphysema, resulting in moderate effects only in
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Key messages
What is the key question?
▸ Is lung volume reduction coil treatment feasible
and does it sustainably improve quality of life
and clinical outcomes in a broad group of
patients with severe emphysema treated in a
multicentre setting?
What is the bottom line?
▸ Bronchoscopic lung volume reduction coil
treatment is associated with a good safety
profile and significantly improves quality of life,
exercise capacity and pulmonary function in a
broad group of patients with severe
emphysema, with sustained results at 1 year.
Why read on?
▸ Further post hoc analysis of CT scan
heterogeneity showed significant responses in
both heterogeneous and homogeneous
emphysema, suggesting that lung volume
reduction coil treatment may benefit patients
with both heterogeneous and homogeneous
emphysema disease distribution.
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the patients with heterogeneous emphysema but without any
serious adverse events. After that first trial we improved the
LVR coil treatment to target the most diseased areas of the lung
with approximately 10 coils placed per lobe, in order to maxi-
mise re-tensioning of the airway network. The results using this
approach in 16 patients with upper lobe predominant heteroge-
neous emphysema have previously been published, showing
feasibility and safety and also demonstrating statistically and
clinically significant improvements in pulmonary function, exer-
cise capacity and quality of life.10 Surprisingly, even in this early
pilot phase, two-thirds of the patients treated responded beyond
the minimal clinically important differences (MCID) for forced
expiratory volume in 1 s (FEV1),
11 residual volume (RV),12
6-min walk distance (6MWD)13 and St George’s Respiratory
Questionnaire (SGRQ).14
Following the successful early experiences in these two pilot
trials, the current study allowed further investigation into the
feasibility, safety and efficacy of LVR coil treatment in a multi-
centre setting in a larger group of patients.
METHODS
This prospective open-label multicentre feasibility study was
conducted in 11 hospitals in France, Germany and the
Netherlands and was approved by the ethics committee at each
site. The first patient was enrolled in December 2009 and the
final patient in October 2011. The initial protocol proposed a
follow-up period of 6 months following initial treatment.
However, because the Dutch and French ethics committees
required a 12-month follow-up period, the protocol was modi-
fied to require a 12-month follow-up for patients in the
Netherlands and France, while maintaining the original
6-month follow-up period for patients in Germany. This paper
reports on all patients in the study at both exit points.
Patients
Patients with COPD with upper or lower lobe predominant
bilateral heterogeneous emphysema on chest CT scan as judged
by the treating physician were considered for inclusion. All
patients were intended to be treated bilaterally, in accordance
with the protocol assessment schedule. The inclusion and exclu-
sion criteria are presented in box 1.
Lung volume reduction (LVR) coil treatment
LVR coil treatment was performed as previously described.10
Briefly, the RePneu LVR coil (PneumRx, USA) (figure 1) is an
implantable device composed of preformed nitinol wire which
is straightened for delivery via a therapeutic flexible broncho-
scope into subsegmental airways using a special delivery cath-
eter, cartridge and loading forceps. Once in place, it is released
and recovers to a non-straight predetermined shape upon
deployment. Seven sizes of coil were available (70, 85, 100,
125, 150, 175 and 200 mm). All procedures were performed
under general anaesthesia and the deployment of the coil was
visualised under fluoroscopy. The coils were deployed with the
objective of achieving equal subsegmental distribution through-
out one target lobe. The contralateral procedure was performed
at least 1 month after the first procedure.
Assessments and follow-up
Screening assessments included medical history, physical exam-
ination, dyspnoea assessment by the modified Medical Research
Council dyspnoea scale (mMRC), quality of life assessment by
the SGRQ,15 echocardiogram, pre- and post-bronchodilator
spirometry, lung volume measurements by body plethysmogra-
phy,16 6MWT,17 chest X-ray and a thoracic CT scan.
The patient was kept at least overnight after the procedure. A
1-month follow-up evaluation was performed, after which the
second procedure was scheduled. Patients were then followed at
1, 3, 6 and 12 months (the latter only in France and The
Netherlands).
Primary/secondary endpoints and safety objectives
The primary efficacy endpoint was the improvement in SGRQ
total score from baseline compared with the score at 6 months.
The secondary efficacy endpoints were the comparison between
baseline and 6 months for forced vital capacity (FVC), FEV1,
RV, residual volume to total lung capacity (RV/TLC) ratio,
improvement in 6MWD and mMRC score. The responder rate
Figure 1 Fully deployed nitinol RePneu lung volume reduction coil.
Box 1 Main study inclusion and exclusion criteria
Main inclusion criteria
▸ >35 years of age
▸ CT scan indicates bilateral heterogeneous emphysema
▸ Post-bronchodilator FEV1 <45% of predicted
▸ Total lung capacity >100% of predicted
▸ RV >175% of predicted
▸ mMRC >2 (0–4)
▸ Stopped smoking for >8 weeks prior to entering the study
Main exclusion criteria
▸ Change in FEV1 >20% post-bronchodilator
▸ TLCO <20% of predicted
▸ History of recurrent clinically significant respiratory infection
▸ Pulmonary hypertension: right ventricular pressure
>50 mm Hg
▸ Inability to walk >140 m in 6 min
▸ Previous LVR surgery, lung transplant or lobectomy
▸ Clinically significant bronchiectasis
▸ Giant bullae more than one-third lung volume
▸ Severe destructed homogeneous emphysema by CT scan
▸ Patient on antiplatelet agent (eg, clopidogrel) or
anticoagulant therapy (eg, heparin or coumadin) or has not
been weaned off prior to procedure
FEV1, forced expiratory volume in 1 s; LVR, lung volume
reduction; mMRC, modified Medical Research Council dyspnoea
score; RV, residual volume; TLCO, carbon monoxide lung transfer
factor.
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at 6 months was calculated using the MCID defined for FEV1,
11
RV,12 6MWD13 and SGRQ.14
The safety objectives were to identify the number and type of
device-related and procedure-related adverse events related to
the use of the LVR coil.
Post hoc CT scan analyses
Since inclusion in this trial was based on the treating physicians’
visual chest CT judgement, a post hoc analysis was performed
on these CT scans to analyse the relationships between the
response to LVR coil treatment at 12 months follow-up and the
level of heterogeneity assessed by a blinded qualitative visual
4-point tissue destruction score scale (0–25%, 26–50%,
51–75%, >75% visible tissue destruction), as well as by calcu-
lating the percentage area of destruction below −950 Hounsfield
Units (HU) between the upper and lower lobes of both lungs.
Quantitative CT analyses were blinded and performed with
CIRRUS Lung 13.10 (Diagnostic Image Analysis Group
Nijmegen, The Netherlands; Fraunhofer MEVIS, Bremen,
Germany). The lungs and lobes were automatically segmented
and visually inspected. Emphysema was quantified per lobe as an
emphysema score: the percentage of voxels below −950 HU.18
For the visual assessment, a patient was classified as heteroge-
neous if there was a difference of >1 point between ipsilateral
lobes on both sides. For the computerised assessment, a patient
was classified as heterogeneous when the difference for both
lungs in the lung tissue destruction score was >25% at
−950 HU between ipsilateral upper and lower lobes.
Statistics
This trial was powered on the statistical significant difference in
expected SGRQ total score between baseline and the 6-month
follow-up time point using an α<0.05 with a power of 0.90,
taking a patient loss to follow-up of 10% into account.10
Data are presented as mean±SD, except for the presentation
of the five unilateral cases and descriptive statistics on the
detailed procedural results (table 2) where data are expressed as
median (minimum−maximum) or median when appropriate.
The statistical significance of changes from baseline was assessed
by the paired Student t test. A linear regression analysis was per-
formed to associate outcome at 6 months for changes in SGRQ
and 6MWD, using as baseline regressors RV% pred, RV/TLC,
FEV1% pred, FVC, age, carbon monoxide lung transfer factor
(TLCO) and emphysema type (homogeneous or heterogeneous
disease). The models were simple linear with no interactions or
terms higher than first order included; p<0.05 was considered
statistically significant. SAS V.9.3 was used for all analyses. All




Sixty patients were enrolled between December 2009 and
October 2011 and their baseline demographics are shown in
table 1). A total of 115 procedures were performed (5 patients
had unilateral treatment, figure 2) in which a total of 1125 LVR
coils were placed. A median of 10 coils (range 5–15) was placed
per lobe (table 2).
Safety
No periprocedural serious adverse events occurred in the 115
bronchoscopies performed under general anaesthesia. No death
or respiratory failure was reported. A summary of all serious
and non-serious respiratory adverse events is listed in table 3.




Of the 60 patients who were bilaterally treated, 58 were evalu-
able at 6 months and 34 at 12 months (24 patients from
Germany exited the study at 6 months). Because the German
cohort exited the study at 6 months, we segregated the data to
compare patients with 1-year follow-up data against their own
6-month results to analyse the sustainability of the clinical
improvements within the same population (table 4). Across key
clinical parameters, FEV1% pred, RV% pred and SGRQ results
were sustained while mean 6MWD actually improved between
6 and 12 months. The MCID responder percentages for FEV1,
RV, 6MWD and SGRQ are shown in table 5.
Unilateral patients
Five patients were treated unilaterally. The reasons for treating
only one lung were: lost to follow-up in two patients; second
lung on second look not suitable for treatment (bullae) in one
patient; and second lung declined by two patients (one
improved satisfactory and one did not want to proceed with the
trial). At 6-month follow-up in four evaluable patients, the
median change in FEV1 was +4.7% (range −17.8% to
+17.0%), median change in 6MWD was +29 m (range −46 m
to +92 m) and RVand RV/TLC remained stable.
Heterogeneous versus homogeneous disease
In the 33 bilaterally treated patients with 12 months follow-up,
the post hoc visual qualitative CT score of the degree of tissue
destruction classified 20 patients as heterogeneous and 13 as
homogeneous. When using the CT software analysis, 16 patients
were classified as heterogeneous and 17 as homogeneous.
Regardless of the classification method, both heterogeneous and
homogeneous patients showed significant improvement at 1 year
(table 6).






FEV1, % pred 30.17±6.32
FVC, L 2.49±0.78
FVC, % pred 73.95±16.94
FEV1/FVC 0.34±0.07
RV, L 5.29±1.32




Supplemental oxygen 35/60 (58%)
mMRC, points 3.0±0.75
Data are shown as mean±SD.
BMI, body mass index; FEV1, forced expiratory volume in 1 s; FVC, forced vital
capacity; mMRC, modified Medical Research Council dyspnoea score; 6MWD, 6-min
walking distance; RV, residual volume; RV/TLC, residual volume to total lung capacity
ratio; SGRQ, St George’s Respiratory Questionnaire total score.
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Upper versus lower lobe disease
In this trial lower lobe treatment was performed in 10 patients,
of whom nine could be evaluated at the 6-month endpoint.
Except for FEV1 (+0.04±0.08 L for lower lobe vs +0.15±0.23
L for upper lobe; p=0.026), there were no statistically signifi-
cant differences in the clinical responses between patients with
upper versus lower lobe disease for RV, 6MWD and SGRQ.
Responder analysis
To identify LVR coil treatment responders we performed a mul-
tivariable analysis for the primary endpoint SGRQ and for the
6MWD. None of the input regressors (RV% pred, RV/TLC,
FEV1% pred, FVC, age, TLCO and emphysema type) were useful
in associating patient outcomes at 6 months.
DISCUSSION
This prospective multicentre study assessed the long-term safety
and improvements in patient-related outcome measures of LVR
coil treatment in 60 patients with severe emphysema. The
results show an acceptable safety profile associated with a signifi-
cant and sustained improvement over 12 months in relevant
clinical and functional parameters including FEV1, RV, 6MWD
and SGRQ.
This is the largest LVR coil study to date, and also evaluated
longer-term results of LVR coil treatment. In our first pilot study
(n=16) using the current treatment approach (median 10 coils
per lung) and coil design, significant clinical and functional
improvements were seen at 6 months including SGRQ (−14.9
points), FEV1 (+14.9%), RV (−11.4%) and 6MWD (+84 m)
with an acceptable safety profile.10 Recently, Shah et al19
reported the results at 90 days after bilateral LVR coil treatment
for 46 patients included in a randomised controlled study and
demonstrated a significant improvement in SGRQ (−8.1 points),
FEV1 (+14%), RV (−0.51 L) and 6MWD (+51 m), with no dif-
ference in serious adverse events between treatment and control
groups.
Figure 2 Study flow chart.
Table 3 Adverse events
Treatment–
1 month >1–6 months >6–12 months
Events Patients Events Patients Events Patients
Serious respiratory adverse events
COPD exacerbation 7 7 12 10 4 3
Pneumonia 6 5 3 3 6 6
Haemoptysis 1 1 0 0 0 0
Pneumothorax 4 4 2 2 1 1
Respiratory adverse events
COPD exacerbation 8 7 21 15 19 15
Pneumonia 5 3 4 3 3 3
Mild haemoptysis
(<5 mL)
61 35 3 3 2 2
Cough 2 2 3 3 0 0
Transient chest
pain
28 20 7 6 3 3
Adverse events presented per procedure for the first month after each procedure (115
procedures in total), for patients in the 1–6 month follow-up period (n=58) and for
patients in the 6–12 month follow-up period (n=35). Events reported for both
unilateral and bilateral treated patients.
COPD, chronic obstructive pulmonary disease.
Table 2 Lung volume reduction coil procedural results




Post-procedure hospital stay, days
Mean 2.3±2.8
Median 1.0 (0–19)
Coils per procedure, n
Mean 9.8±1.4
Median 10 (5–15)
Total coils implanted 1125
Upper, right lobe 437
Upper, left lobe 450
Lower, right lobe 110
Lower, left lobe 121
Middle, right lobe 7








Dataare shown as numbers, mean±SD or median (minimum − maximum).
LVR, lung volume reduction.
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In the present multicentre study involving 11 centres, no
serious adverse events were reported during the LVR coil treat-
ment procedures, demonstrating procedural safety. Serious
adverse events (table 3) mainly occurred in the 30 days after the
procedure, with all events resolving with regular medical care
and without sequelae. Our results confirm the acceptable safety
profile for LVR coil treatment with a rate of adverse events
similar to previous reports on LVR coil treatment.10 19 The rate
of post-procedure exacerbations and pneumonia is comparable
to reported events with endobronchial one-way valves.6 8
Importantly, the total rate of these COPD-related events follow-
ing endoscopic implants did not exceed the number of exacerba-
tions and pneumonia that were reported in the EASE trial sham
bronchoscopy control group.20 LVR coil specific
procedure-induced events that occur are typically very mild
haemoptysis or coloured sputum requiring no intervention in
about 50% of subjects and temporary chest discomfort for a few
days requiring either a standard painkiller regimen for a few
days or no intervention at all in about one-third of subjects
treated.
Regarding efficacy, our results show significant improvements
in clinical and functional parameters at 6 months with a magni-
tude of response in line with the two recent reports on LVR coil
treatment,10 19 reporting on 6- and 3-month follow-up, respect-
ively. Our study provides the first longer-term analysis of data
over 12 months after bilateral LVR coil treatment and demon-
strates a sustained response at 12 months. To better analyse the
relevance of the efficacy results, we analysed the MCID in
FEV1,
11 RV,12 6MWD13 and SGRQ14 and found a significant
responder rate at 6 and 12 months for these clinical endpoints
(table 5).
The cohort trial design can, of course, induce bias. However,
the results reported are higher than reported MCID for our
endpoints and show similar efficacy across multiple centres.
Furthermore, we have previously shown that, even in a sham-
controlled bronchoscopic interventional trial design, no real
placebo effect could be observed in patients with severe
COPD.20
To better understand the predictors of response to LVR coil
treatment, we conducted a multivariate analysis to assess the rela-
tionship between the response to treatment and baseline variables
typically identified as predictors of outcome, such as hyperinfla-
tion and emphysema heterogeneity. Using the 6-month end-
points, none of the evaluated baseline variables provided a
meaningful predictor of response to LVR coil treatment. Other
potential variables could include nuanced emphysema pheno-
types beyond heterogeneous or homogeneous classification, such
as more or less small airways disease, centrilobular versus panlob-
ular emphysema and variability in placement strategies including
proximal versus distal placement within the subsegmental
airways and/or the number and size of coils deployed. The
current active clinical trials (NCT0182279521 and
NCT01608490) and future meta-analysis data of patients treated
in the four European clinical studies thus far may increase the
statistical power sufficiently to perform this analysis better. In
our study, where broad selection criteria were purposely used in
order to evaluate the effectiveness in a population of patients rep-
resentative of the patients we see in daily practice, we found a
large variability of response between patients. However,
responder rates overall for several endpoints were already high
(table 5).
The difficulty of identifying strong predictors of success has
been previously demonstrated by a predictive multivariate effort
completed in a much larger patient cohort (n=608) for
outcome after lung volume reduction surgery. In this large
group, only a very weak signal for RV/TLC and emphysema dis-
tribution could be demonstrated.22
Lung hyperinflation is a major feature of emphysema and is
associated with dyspnoea, exercise intolerance and compromised
daily physical activity.23 24 In this study, neither baseline RV nor
RV/TLC predicted the response to LVR coil treatment. This is
Table 4 Efficacy results at 6 and 12 months







FEV1, L +0.11±0.20 (n=54, p<0.001) +0.12±0.28 (n=33, p=0.021) +0.11±0.30 (n=34, p=0.037)
FEV1, % pred (% change) +15.36±26.68 (n=54, p<0.001) +17.81±31.71 (n=33, p=0.003) +16.04±35.54 (n=34, p=0.017)
FVC, L +0.20±0.53 (n=54, p=0.008) +0.33±0.57 (n=33, p=0.002) +0.28±0.45 (n=34, p=0.001)
RV, L −0.65±0.90 (n=58, p<0.001) −0.80±1.03 (n=34, p<0.001) −0.71±0.81 (n=34, p<0.001)
RV, % pred (% change) −11.31±15.25 (n=58, p<0.001) −14.38±15.42 (n=34, p<0.001) −13.75±12.65 (n=34, p<0.001)
RV/TLC −4.51±12.19 (n=58, p=0.007) −6.06±8.58 (n=34, p<0.001) −3.12±15.59 (n=34, p=0.245)
6MWD, m +29.7±74.1 (n=56, p=0.004) +42.4±73.5 (n=34, p=0.002) +51.4±76.1 (n=32, p=0.003)
SGRQ, points −12.1±12.9 (n=56, p<0.001) −10.4±15.8 (n=33, p<0.001) −11.1±13.3 (n=32, p<0.001)
mMRC, points −0.6±1.2 (n=58, p<0.001) 0.8±0.9 (n=34, p<0.001) −0.7±0.8 (n=34, p<0.001)
Efficacy at 6 months for all LVR coil treatments (n=58, overall group) and at 6 and 12 months (n=34, 12-month follow-up group columns). Results are given as change from baseline.
Data are shown as mean±SD.
Data in parentheses are the numbers of actual measurements available per variable tested followed by the actual p value.
6MWD, 6-min walking distance; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; mMRC, modified Medical Research Council dyspnoea score; RV, residual volume;
SGRQ, St George’s Respiratory Questionnaire total score; TLC, total lung capacity.
Table 5 Responder rates at 6 and 12 months
Variable MCID 6 months (%) 12 months (%)
FEV1 ≥12%11 48.0 40.6
RV ≥0.3512 64.8 57.6
6MWD ≥26 m13 52.8 60.0
SGRQ ≥4 points14 74.1 65.6
SGRQ ≥8 points 61.1 53.1
Responder rates at 6 and 12 months after bilateral lung volume reduction coil
treatment using minimal clinically important differences (MCID) for forced expiratory
volume in 1 s (FEV1), residual volume (RV), 6-min walking distance (6MWD) and the
St George’s Respiratory Questionnaire total score (SGRQ). Results are given as
percentage of responders to total patients.
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possibly due to the fact that RV >175% pred was an inclusion
criterion, resulting in treatment of severe static hyperinflated
patients (mean baseline RV 249.2±53.2% pred). On the other
hand, the magnitude of change in RV after LVR coil treatment
was associated with more favourable mean clinical and func-
tional outcomes in this study, suggesting that RV changes may
be viewed as a marker of response to treatment and that, by
selecting patients with more potential for significant RV
decrease, the likelihood of significant clinical benefit may be
increased. The finding that RV is reduced by LVR coil treatment
might be related to mechanical volume compression of lung
tissue exerted by the coils, as well as improvement in elastic
recoil achieved by decreasing airway resistance.25
When comparing the results for patients with upper lobe
versus lower lobe treatment, no outcome differences were
observed for RV, 6MWD and SGRQ. The lower FEV1 results
seen with lower lobe coil treatments is comparable to the
experience with lung volume reduction surgery in the lower
lobes where the effect on improving FEV1 is also limited com-
pared with other outcome variables.26 However, because FEV1
in general shows poor correlation with performance in patients
with severe emphysema,27 and that patient-relevant outcomes
such as 6MWD and SGRQ show strong improvement even in
lower lobe subjects, lower lobe treatment with coils appears to
be a clinically valid treatment option with clear patient benefit.
Future work will evaluate whether, as currently hypothesised,
the much bigger lower lobes require a greater number of coils to
optimise results.
Our post hoc CT analysis showed that a large number of
patients were classified as homogeneous when using both a
visual and a digital assessment, even though the inclusion cri-
teria called for heterogeneous patients per clinicians’ visual
assessment. This finding should be cautiously considered, since
this trial was not designed to prospectively identify homoge-
neous emphysema patients and the two methods of creating a
heterogeneous versus a homogeneous group are arbitrary. Our
results show that LVR coil treatment also benefits patients with
less pronounced heterogeneous to homogeneous disease. Our
data showed a statistically and clinically significant benefit for
both groups compared with baseline, with overall a potentially
increased mean efficacy for the heterogeneous patient group.
The fact that LVR coil treatment also shows efficacy in patients
with homogeneous emphysema is a very important finding,
challenging the assumption that only patients with heteroge-
neous emphysema will respond to LVR coil treatment, as has
been shown for surgical lung volume reduction28 and EBV.6 7
Of note, other bronchoscopic techniques such as thermal
vapour ablation29 and sealant therapy30 are also restricted to
upper lobe predominant heterogeneous emphysema, leaving a
broad group of patients with non-upper lobe predominant and
homogeneous disease without a treatment option. It can be
hypothesised that LVR coil treatment is similarly efficient in
both heterogeneous and homogeneous emphysema because of a
different mechanism of action from true ‘lung volume reducing’
therapies, as the primary mechanism of action of coils appears
to be mechanical re-tensioning of the airway network rather
than just reducing absolute lung volume alone. However, add-
itional studies are necessary to better characterise the mechan-
isms of action of coils and also to confirm the efficacy of LVR
coil treatment in homogeneous emphysema, which represents a
large number of patients usually excluded from other surgical
and bronchoscopic lung volume reduction treatment options.
In conclusion, this study provides multicentre evidence for
the feasibility, procedural safety and efficacy of LVR coil treat-
ment in patients with both heterogeneous and homogeneous
emphysema. Further studies are underway to confirm efficacy in
long-term randomised trials. Additional studies are needed to
improve the understanding of the predictive factors of response
in order to better select the responders to LVR coil treatment.
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Table 6 Results at 12 months after bilateral LVR coil treatment for patients classified as heterogeneous and homogeneous emphysema
Visual CT assessment* Digital CT assessment*
(12 month follow-up group) (12 month follow-up group)
Heterogeneous (n=20) Homogeneous (n=13) p Value Heterogeneous (n=16) Homogeneous (n=17) p Value
ΔFEV1, L +0.14±0.30 +0.08±0.28 0.585 +0.18±0.32 +0.05±0.26 0.220
ΔRV, L −0.69±0.87 −0.68±0.46 0.859 −0.75±0.78 −0.66±0.72 0.719
Δ6MWD, m +53.9±65.1 +46.0±67.9 0.739 +74.9±67.4 +27.9±57.8 0.049
ΔSGRQ, points −12.9±15.1 −7.3±8.7 0.187 −12.4±13.9 −9.1±12.9 0.491
Results are given as mean±SD change from baseline. Heterogeneity and homogeneity were assessed by both a visual CT assessment (a 4-point qualitative score of the degree of tissue
destruction where a difference of ≤1 point for both lungs was regarded as homogeneous) and a digital CT assessment (where the software calculated the percentage area of
destruction at –950 Hounsfield Units; a difference of ≤25% in destruction for both lungs was regarded as homogeneous).
6MWD, 6-min walking distance; FEV1, forced expiratory volume in 1 s; LVR, lung volume reduction; RV, residual volume; SGRQ, St George’s Respiratory Questionnaire total score.
*p<0.05 for all end-points compared to baseline.
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